Introduction {#S1}
============

The mammalian brain depends on a constant supply of oxygen (O~2~) to meet its energy needs, and a host of adaptive responses have evolved to protect brain O~2~ levels. Prominent among these is the biphasic hypoxic ventilatory response ([@B137]) in which a fall in arterial O~2~ detected at the carotid body chemoreceptors triggers, within the first minute of exposure, an adaptive (Phase 1) increase in breathing. If this increase does not immediately restore arterial O~2~, the brain becomes hypoxic, triggering changes in brain chemistry and a maladaptive secondary hypoxic respiratory depression during which ventilation gradually decreases (4--5 min) to a lower steady-state (Phase 2) level. The secondary depression is especially pronounced in premature mammals, where ventilation falls below baseline and can become life-threatening ([@B137]; [@B15]; [@B139]).

Mechanistically, the biphasic hypoxic ventilatory response has been viewed for decades as the result of just two interacting processes; an initial peripheral, carotid body-mediated (Phase 1) excitation and a slower, centrally mediated hypoxic respiratory depression to a steady-state (Phase 2) level of breathing ([@B137]; [@B139]). The mechanisms underlying this depression are not fully understood, but adenosine is strongly implicated ([@B137]; [@B15]; [@B139]). The key point is that according to this conventional view of the hypoxic ventilatory response, excitation of breathing during hypoxia derives solely from the peripheral nervous system; i.e., the only contribution of the central nervous system to the hypoxic ventilatory response is depression.

New evidence from key cardiorespiratory control sites is challenging this dogma. In relation to the cardiovascular system, C1 noradrenergic neurons involved in control of heart rate and blood pressure are powerfully excited by hypoxia and this excitation is important for homeostatic control ([@B77]). In the respiratory network, while the Phase 1 component of the hypoxic ventilatory response is mediated peripherally, our data from rodents strongly suggest that during hypoxia, astrocytes in the preBötzinger Complex (preBötC, critical site for generating breathing rhythm) detect hypoxia and release ATP, which, via P2Y~1~ receptors, excites inspiratory neurons and increases ventilation, thereby attenuating the hypoxic respiratory depression ([@B75]; [@B6]; [@B151]; [@B170]). Thus, unlike the majority of brain regions where hypoxia has depressant actions, the astroglial network of the preBötC appears to mount an excitatory response that partially counteracts the hypoxic respiratory depression, contributing to a vital homeostatic reflex.

The effects of extracellular ATP (ATPe), however, are not determined solely by its actions on P2 receptors. ATPe is rapidly broken down by ectonucleotidases (e.g., Cd39, CD73) into extracellular adenosine diphosphate (ADPe), adenosine monophosphate (AMPe) and ultimately adenosine (ADOe), a transmitter in its own right that signals via 4 types of P1 receptors, A1, A2A, A2B, and A3 ([@B78]; [@B169]). Indeed a predominant effect of hypoxia (and ischemia) on brain chemistry is a widespread increase in the concentration of extracellular adenosine (ADOe) (reviewed by [@B43]) that can derive from multiple sources including vesicular release of ATP as a transmitter/cotransmitter that is subsequently degraded, and export of intracellular ADO (ADOi) (reviewed by [@B113]). In the brain ADOe acts primarily through low affinity A1 and A2A receptors to elicit a host of region-specific effects, largely by modulating glutamatergic transmission. A1 receptor-mediated inhibitory mechanisms, pre- and postsynaptic, are widespread and can be considered neuroprotective ([@B197]; [@B22], [@B24]). A2A receptors are primarily excitatory and engaged in adaptive processes, as heralded by their key role in synaptic plasticity in different brain areas ([@B57], [@B56]; [@B148]; [@B184]; [@B40]; [@B32]; [@B122]). Within the brainstem network that generates and controls breathing, ADOe is largely inhibitory, which in this network is maladaptive; i.e., for the body/brain to recover from hypoxia and restore O~2~ homeostasis, ventilation and cardiac activity must increase. ADOe inhibits breathing most potently in premature and newborn mammals via A1 receptors in the preBötC ([@B85]; [@B84]; [@B87]; [@B209]) and A2A receptor-mediated excitation of brainstem GABAergic neurons ([@B106], [@B103]; [@B200]; [@B132]). Indeed the inhibitory actions of ADOe on the central respiratory network are strongly implicated in the respiratory depression that is life-threatening in apnea of prematurity (AOP) ([@B131]; [@B67]; [@B149]; [@B30]), and fatal in sudden infant death syndrome (SIDS) and sudden unexpected death in epilepsy (SUDEP) ([@B23]; [@B158]).

Thus, the actions of ATP in the preBötC are likely determined by the balance between the excitatory actions of ATP (and ADP) at P2 receptors and the inhibitory actions of its main metabolite, ADO, at P1 receptors ([Figure 1](#F1){ref-type="fig"}). Indeed, this balance, which is controlled by a complex signaling system referred to as the *purinome* ([@B193]; [Figure 2](#F2){ref-type="fig"}), is emerging as important in determining the degree of hypoxic respiratory depression ([@B67]; [@B6]; [@B74]; [@B151]; [@B68]). The purinome includes: ATPe and P2 receptors (1,2 in [Figure 2](#F2){ref-type="fig"}), ADOe and P1 receptors (4); ectonucleotidases that degrade ATP into ADO (3); equilibrative and concentrative nucleoside transporters (ENTs and CNTs, respectively) ([@B94]; [@B144]; [@B205]) that move ADO across membranes down (ENTs) or against (CNTs) the ADO concentration gradient (5); and intracellular metabolic enzymes such as adenosine kinase (ADK) ([@B23]) that keep ADOi levels low and control the direction of ADO transport by ENTs (7) ([@B23]). Astrocytes also contribute through their ability to release and respond to ATP and ADO, degrade ATP and remove ADOe. This integrated view of the purinome has influenced epilepsy researchers in the development of novel strategies for manipulating endogenous levels of ADOe to combat seizures ([@B21]; [@B158]). Previous work exploring the contribution of purinergic signaling to the hypoxic ventilatory response has been neurocentric and focused primarily on the actions of ADO at P1 receptors. Thus, contrary to the long-held view that the biphasic hypoxic ventilatory response is due to two competing processes, we propose at least three processes, a peripheral carotid body mediated excitation that underlies Phase 1, as well as central excitatory and inhibitory processes that interact to determine the time course and magnitude of the secondary depression; we also propose a key role for glia in this central excitation. Here, we first discuss the clinical significance of understanding the hypoxic ventilatory response. We then present our working hypothesis of the significance of purinergic signaling in the hypoxic ventilatory response from the broader perspective of the purinome, summarize what is known about the roles played by each component of the purinome in this response and highlight some of the important challenges/questions that remain. Our purpose is not to provide an exhaustive review of all purinergic mechanisms and their influence on information processing in the CNS, but to focus on those most relevant to understanding purinergic signaling in the preBötC and its contribution to the hypoxic ventilatory response. We draw from the insights about purinergic signaling that come from other systems, especially the Schaffer collateral-CA1 pyramidal neuron synapse in the hippocampus, and consider potential implications of identified mechanisms in the context of what is known in respiratory control. For those interested in the control of breathing, the goal is familiarity with the complexities of purinergic systems and potential implications for respiratory control in health and disease. For those with expertise in purinergic signaling, the goal is an appreciation of the unique opportunities for advancing understanding of purinergic signaling that might come with analysis of the central neuro-glial networks that control breathing \[the contribution of purinergic signaling to hypoxia sensing in the carotid body is reviewed elsewhere ([@B111]; [@B36]; [@B114]; [@B141])\].

![The effects of ATP released into the extracellular space is determined by a balance between actions of ATP at P2 receptors and ADO, its main metabolite, at P1 receptors. Extracellular ATP has two main fates, binding to P2 receptors (1) or degradation by diverse ectonucleotidases (ECTOs) (2) with differential substrate affinities that degrade ATP and its by-products ultimately to adenosine (ADO). Extracellular ADO has three main fates, binding to P1 receptors, transport into the intracellular space or remaining where it is. The balance is dynamic and determined by a complex system referred to as the purinome (see [Figure 2](#F2){ref-type="fig"}) (Modified with permission from [@B67]).](fncel-13-00365-g001){#F1}

![Simplified schematic of the purinome at a glutamatergic, inspiratory, preBötC synapse: multiple factors determine the balance between ATP and ADO signaling. During inspiration, a volley of action potentials in the presynaptic neuron evokes glutamate release that depolarizes the postsynaptic inspiratory neuron via activation of glutamate receptors (ionotropic and metabotropic, mGluR). Hypoxia stimulates astrocytes, via a mitochondrial mechanism (not shown) that evokes increased intracellular Ca^2+^ and vesicular ATP release (1). (2) ATPe acts via neuronal P2 (primarily P2Y~1~) receptors to excite inspiratory neurons and increase ventilation via a process involving increased intracellular Ca^2+^. Extracellular ADO (ADOe) increases through breakdown of ATPe by ectonucleotidases (3) or ENT transport of accumulating ADOi (5). ADO acts pre- and postsynaptically via A1 receptors (or A2 receptors on GABAergic neurons, not shown) to inhibit ventilation (4). The direction of ADO transport via ENTs (5) is dependent on the \[ADO\] gradient. Hypoxia also causes accumulation of intracellular ADO (ADOi) from ATPi hydrolysis (6). ADK phosphorylates ADO into AMP (7), keeping ADOi low so that ENTs remove ADOe. The cytoplasmic form of ADK, at least in adult brain, is limited to astrocytes so that removal of ADOe becomes an astrocyte dependent process (Modified with permission from [@B67]).](fncel-13-00365-g002){#F2}

Clinical Significance of the Hypoxic Ventilatory Response {#S2}
=========================================================

Hypoxia and the secondary hypoxic respiratory depression are most severe and life threatening in infants who are born prematurely. This reflects that the brain circuits responsible for the generation and control of ventilation are immature and produce a breathing pattern that is interrupted by frequent apneas (periods where breathing stops; apnea of prematurity). Thus, a potentially fatal positive feedback loop can develop in which an apnea causes hypoxia, hypoxia evokes the hypoxic ventilatory response that features a strong secondary respiratory depression that can exacerbate the hypoxia...and so on. Apnea of prematurity affects ∼1% of all births in Canada; ∼3000 babies/yr ([@B175]). Risk decreases dramatically with gestational age; ∼15% of infants are affected at 32--33 weeks gestational age but nearly 100% at \< 29 weeks ([@B149]). The mechanisms underlying the hypoxic respiratory depression and the greater depression in prematurity are not fully understood. The literature is confusing because the hypoxic respiratory depression varies greatly between species, changes developmentally, and likely involves multiple mechanisms. It also depends on whether the experimental apparatus used to deliver the hypoxic gas can deliver a rapid, step change in oxygen. The hypoxia-evoked, Phase 1 increase in ventilation peaks within the 1st min. If the transition from normoxia to hypoxia produced by the gas delivery system is too slow, the hypoxic stimulus will peak after secondary depressive mechanisms have been activated. The result is that the magnitude of both the Phase 1 increase in ventilation and the secondary depression will be underestimated. Nevertheless, it is clear that while the secondary depression is not entirely due to ADOe, ADOe plays a significant role ([@B131]; [@B67]; [@B149]; [@B30]). Blockade of the respiratory depression by ADO receptor antagonists in a host of species suggests a causative role for ADOe ([@B131]; [@B67]; [@B149]; [@B30]). Virtually all infants born prematurely who have apnea are treated with methylxanthines, purine based respiratory stimulants that antagonize the inhibitory actions of ADO ([@B165], [@B164]). At higher doses that may be relevant clinically, methylxanthines may also inhibit phosphodiesterase activity (preventing cAMP breakdown) and voltage-gated calcium channels ([@B35]); i.e., the actions of caffeine may not all be mediated by P1 receptors.

Caffeine is the preferred methylxanthine for treatment of apnea of prematurity, due to its better safety profile, and efficacy ([@B172]). However, there is still a need for alternate treatment strategies. First, ∼20% of apnea of prematurity patients do not respond to caffeine ([@B165], [@B164]). On average such infants will spend an extra week on ventilator support and face greater rates of lung pathology, cognitive delay and cerebral palsy ([@B165], [@B164]). Second, while generally a very safe drug, acute side effects include tachycardia, hypertension and tremors. In addition, high concentrations (which are more effective at reducing apneas) in preterm infants increase the incidence of cerebellar hemorrhage 2 years later, are associated with significant changes in motor performance ([@B133]) and status epilepticus ([@B19]; [@B172]). There is also the potential for long-term effects on sleep ([@B136]). Hypoxia and hypoxic respiratory depression are also implicated in SUDEP, the sudden, unexplained death of persons with epilepsy ([@B23]; [@B158]; [@B192]). SUDEP is a catastrophic event for which all persons with epilepsy are at risk; most deaths occur in middle age but it can happen at any age. The risk for SUDEP is not trivial. A cohort of children with epilepsy was observed for 40 years; SUDEP occurred in 9% of all patients and accounted for 38% of all deaths ([@B174]; [@B20]). Respiratory arrest appears to be the major cause for SUDEP ([@B50]); a leading hypothesis, the ADO hypothesis of SUDEP, proposes that hypoxia and accumulation of ADOe during a seizure causes a fatal depression of the brainstem respiratory networks ([@B171]). No preventative strategies exist for SUDEP.

Intermittent hypoxia is also common in various forms of sleep disordered breathing in which a combination of a collapsible airway, high arousability, and high loop gain in chemosensory control systems give rise to cyclic apneas ([@B48]) and a dramatic increase in the risk of cardiovascular disease ([@B206]; [@B207]; [@B115]; [@B150]). While the hypoxic ventilatory response and hypoxic respiratory depression are not directly implicated in the cyclic apneas of obstructive sleep apnea, understanding all chemosensory systems, including the novel central hypoxia sensing mechanism under discussion here, is essential to resolve how central and peripheral chemosensory systems interact to cause high loop gain and cyclic apneas that are common in sleep disordered breathing ([@B49], [@B48]; [@B47]).

Efforts to understand purinergic signaling in the hypoxic ventilatory response have largely focused on the inhibitory actions of ADO at P1 receptors, primarily because ADO is so strongly implicated in the profound hypoxic depression in apnea of prematurity ([@B131]; [@B67]; [@B149]; [@B30]). Given the emerging picture that the balance between ATP and ADO signaling in the preBötC is important in determining the degree of respiratory depression during the hypoxic ventilatory response, this focus on ADO receptors needs to expand to other components of the purinome. Understanding how the various components of the purinome affect the balance between ATP and ADO signaling is key to manipulating purinergic signaling to modulate breathing. Indeed, the therapeutic potential of the purinome lies in the diversity of its ATP and ADO receptors, transporters, and enzymes. This is fertile ground that has led to clinical drug trials for cardiac arrhythmias, pain, thrombosis, Parkinson's disease, psoriasis, dry eye, cystic fibrosis, glaucoma and cancer ([@B142]; [@B100]; [@B28]; [@B89]; [@B23]).

Working Model of Purinergic Signaling in the preBötC Inspiratory Synapse During Hypoxia {#S3}
=======================================================================================

We first provide a brief summary of our working model of how the various components of the purinome in the preBötC might shape the hypoxic ventilatory response; note that not all of the indicated pathways have been demonstrated. This summary is followed by a detailed discussion of the data supporting involvement of purinergic signaling in each step of the proposed model that focuses on the types of preparations from which data were derived (culture, *in vitro*, or *in vivo* anesthetized/paralyzed/freely moving). When relevant data are not available from analysis of the respiratory network, we draw on insights made from analysis of glutamatergic synapses in other brain regions, in particular the hippocampus, where the modulation of glutamatergic signaling by purines (and all components of the purinome) is more completely understood.

At the core of the model ([Figure 2](#F2){ref-type="fig"}) are three preBötC cells including an astrocyte, a presynaptic inspiratory glutamatergic neuron, and a postsynaptic, inspiratory glutamatergic neuron. During inspiration a volley of action potentials arrives at the presynaptic terminal, triggers the release of glutamate that acts at ionotropic (primarily AMPA) and metabotropic glutamate receptors and evokes an inspiratory burst. Modulation of rhythm by ATP and ADO during hypoxia is hypothesized to occur through modulation of excitability at multiple synapses like this one between key inspiratory, preBötC neurons that generate rhythm based on their excitatory connections with each other ([@B46]). During hypoxia, astrocytes in the preBötC respond with an increase in intracellular Ca^2+^ and vesicular release of ATP (1). ATPe has two main fates. It binds to P2, primarily P2Y~1~, receptors on inspiratory neurons causing excitation and increased inspiratory frequency, at least in part by activating G~*q*~ proteins and increasing intracellular Ca^2+^ ([@B151]) (2). ATPe, once released into the extracellular space, also immediately begins to undergo degradation by ectonucleotidases (3), producing extracellular ADPe (which is excitatory at P2Y~1~ receptors), AMPe and finally ADOe, which binds to pre- and postsynaptic A1 receptors that inhibit inspiratory rhythm (4). This sets up the very dynamic interaction between the excitatory actions of ATPe (and ADPe) at P2 receptors (2) and inhibitory actions of ADOe at A1 receptors (4). The dynamics will be determined by all elements of the purinome that likely vary between brain regions, with development and also between the same brain region in different species (see discussion below comparing rat vs. mice ([@B209]). Excitation will be determined by the amount of ATP released, local P2 receptor expression patterns and levels, their downstream signaling cascades, as well as the expression level and local complement of ectonucleotidases that determine the rate of ATP removal. In addition, because different ectonucleotidases have different substrate affinities and reaction products with some preferentially producing ADP (which is excitatory via P2Y~1~ receptors) while others preferentially produce ADO, the mixture of agonists that develops following ATP release depends on the local complement of ectonucleotidases. Inhibition will be determined by local P1 receptor expression patterns and levels, their downstream signaling cascades and the local concentration of ADOe. ADOe accumulates from ectonucleotidase-mediated degradation of adenine nucleotides but it can also come from ENT-mediated transport of ADOi (5) if the concentration of ADO accumulating inside cells from ATP hydrolysis (6) during hypoxia exceeds ADOe. Importantly, the availability of ADOe and hence the level of neuronal ADO receptor activation is largely under the control of ADK (7), expressed in astrocytes (at least in adults). Intracellular phosphorylation of ADO into AMP in astrocytes keeps ADOi levels sufficiently low to drive the influx of ADOe into astrocytes via ENT facilitated transport. Thereby, astrocytes assume a role as a metabolic sink for ADOe and for the termination of ADO receptor activation. The main points of [Figure 2](#F2){ref-type="fig"} are first that the balance between P2 and P1 receptor signaling is very dynamic and determined by multiple factors, many of which remain to be examined for their impact on the hypoxic ventilatory response. Second, in contrast to the long-held view that the biphasic hypoxic ventilatory response results from just two interacting processes \[an initial peripheral, carotid body-mediated (Phase 1) excitation and a slower, centrally mediated hypoxic respiratory depression ([@B137]; [@B139])\], we propose that following the Phase 1 increase, central purinergic mechanisms, excitatory and inhibitory, interact in the preBötC and perhaps elsewhere to shape the remainder of the hypoxic ventilatory response.

While the initial increase indeed appears to be mediated by peripheral chemoreceptors, whether a central excitatory component helps shape the hypoxic ventilatory response during Phase 2 remains controversial and readers are referred to a recent Cross-Talk debate in the Journal of Physiology for a detailed discussion ([@B68], [@B69]; [@B180], [@B181]). Several points of consensus came from that Cross-Talk. First, there was general agreement that gradual recovery, or lack of recovery, of an excitatory component to the hypoxic ventilatory response following carotid body denervation is unlikely to be informative as the same data could be interpreted to support or refute either position. For example, while the frequently observed loss of an hypoxia-evoked increase in ventilation after carotid body denervation is compelling evidence that there is no central contribution to the hypoxia-induced increase in ventilation, there is an alternate interpretation. The lack of response could result from the loss of a tonic, non-chemosensory related carotid body input that is necessary for central hypoxia sensing mechanisms to be expressed. Indeed, unanesthetized dogs and goats with separately perfused, normoxic carotid bodies respond to central hypoxia with a slow onset increase in ventilation that is lost once the normoxic carotid bodies are denervated ([@B44]; [@B42]). Conversely, gradual recovery of an excitatory ventilatory response to hypoxia in carotid body-denervated animals is often cited as strong evidence of a central contribution, but this recovered response could also be the result of plasticity. Indeed, carotid body denervation triggers considerable plasticity in peripheral and central neural networks involved in the control of breathing ([@B182]). Second, the need for reduced preparations to delineate cellular/ionic/molecular mechanisms of O~2~ sensing was acknowledged, but so was the importance of acknowledging the limitations of data derived from such preparations. Finally, there was consensus that the real arbiter of the physiological relevance of central hypoxia sensing mechanisms is what happens in unanesthetized animals with intact carotid bodies when putative central oxygen sensing mechanisms are selectively (and reversibly) perturbed. Progress toward this goal, via the application of viral approaches to selectively (but not yet reversibly) manipulate central purinergic and glial signaling mechanisms *in vivo*, is summarized below.

Components of the Purinome and their Role(s) in the Hypoxic Ventilatory Response {#S4}
================================================================================

Role for ATP and Astrocytes {#S4.SS1}
---------------------------

Hypoxia-evoked ATP release of unknown origin was first detected using ATP sensors placed on the ventral medullary surface of anesthetized rats ([@B75]; [@B6]; [@B151]). Hypoxia-induced increases in intracellular Ca^2+^ fluorescence of cortical astrocytes in anesthetized rats suggest that astrocytes are directly sensitive to hypoxia. Direct sensitivity was confirmed with the demonstration that cultured astrocytes respond to hypoxia with an increase in mitochondrial reactive oxygen species that activate PLC, causing an increase in intracellular Ca^2+^ and exocytotic release of ATP (not shown in [Figure 2](#F2){ref-type="fig"}); ATP release was shown directly using TIRF (total internal reflection fluorescence) imaging to reveal hypoxia-induced disappearance of ATP-containing vesicles from the intracellular surface of astrocyte membranes ([@B6]).

Astrocytic ATP release was also shown indirectly in awake, carotid body-intact animals using viral approaches to block astroglial vesicular release mechanisms (injection of adenoviral vectors that expressed either the light chain tetanus toxin or the dominant-negative SNARE protein in astrocytes) or increase ATP degradation (injection of lentiviral vector that increased ectonucleotidase expression on all cells) at the level of the preBötC; both treatments consistently reduced the hypoxic ventilatory response ([@B6]; [@B170]). These treatments in anesthetized, carotid body intact or carotid body denervated rats similarly decreased the hypoxic ventilatory response ([@B6]; [@B151]).

These data make a strong case for an ATP-mediated, excitatory contribution to the hypoxic ventilatory response. A caveat remains regarding the case for an astrocytic contribution. The recent demonstrations that disruption of vesicular release mechanisms in astrocytes using the same viral tools attenuates the hypercapnic ventilatory response and exercise capacity as well as the hypoxic ventilatory response ([@B129]; [@B170]) have raised the concern that viral injection disrupts baseline astrocyte functions and impairs preBötC excitability. We consider this unlikely because control viruses were without effect on the hypoxic ventilatory response, the hypercapnic ventilatory response and exercise capacity. Thus, while it will be important to demonstrate that the viral tools used to disrupt astrocytic signaling *in vivo* do not globally impair preBötC responsiveness, we propose that the attenuation of respiratory responses to elevated ventilatory drive or metabolic demand following block of vesicular release mechanisms in preBötC astrocytes supports that astrocytes act as brain metabolic sensors ([@B129]).

P2 Receptors {#S4.SS2}
------------

ATP acts through seven subtypes of ionotropic P2X and eight subtypes of metabotropic P2Y receptors ([@B3]; [@B29]; [@B30]). Our focus is on P2Y~1~ receptors because they are exclusively responsible for the marked frequency increase evoked by ATP in the preBötC in medullary slices that generate inspiratory-related rhythm *in vitro*. However, P2Y~1~ receptor effects are not always excitatory and vary between brain regions. For example, in hippocampus P2Y~1~ receptor activation reduces glutamate release ([@B159]), but also excites inhibitory interneurons ([@B93]). Lamina IX spinal cord neurons are also directly excited by P2Y~1~ receptor activation ([@B7]). In the preBötC, MRS 2179 and MRS 2279 (P2Y~1~ receptor antagonists) completely block the network response evoked by exogenous ATP *in vitro*, while PPADS and Suramin (general P2 antagonists with low affinity for P2Y~1~ receptors) and TNP-ATP (P2X~1,3~ antagonist) are without effect ([@B126]; [@B87], [@B86]). *In vivo*, bathing the ventral medullary surface of anesthetized rats with PPADS (10 μM) or unilaterally injecting the P2Y~1~ antagonist MRS 2279 into the preBötC of paralyzed rats reduces the hypoxic ventilatory response, indicating that P2Y~1~ receptors, and possibly other P2 receptors, contribute to the central, hypoxia-mediated increase in ventilation ([@B75]; [@B6]; [@B151]). Potentiation of P2Y~1~ receptor signaling may therefore be one approach through which respiratory activity could be enhanced to counteract respiratory depression.

These data add to a growing body of evidence that the preBötC is unique. Not only is it key for inspiratory rhythm generation ([@B61]), generation of sighs ([@B116]) and coordinating multiple orofacial behaviors ([@B95], [@B96]), it also mounts an excitatory response to hypoxia ([@B6]; [@B74]; [@B151]). An important remaining task is to define 2nd messenger cascades, ionic mechanisms and neuronal phenotype(s) that underlie the ATP excitation of the preBötC that occurs during hypoxia. P2Y~1~ receptors conventionally signal via the G~*q*~ cascade ([@B2]), but the cascade activated in the preBötC has not been identified. Candidate ion channels, i.e., those that affect preBötC rhythm and are also modulated by P2Y~1~ receptors, include TASK, KCNQ, L-, P-, Q-, and N-type voltage-gated Ca^2+^ channels, BK and SK, and I~*CAN*~ (Ca^2+^-activated non-selective cation channels) ([@B152]). A key question is whether the subgroup of preBötC neurons that respond to P2Y~1~ receptor activation and mediate the increase in network frequency are excitatory (i.e., glutamatergic) or inhibitory (GABA- or glycinergic). The model in [Figure 2](#F2){ref-type="fig"} depicts glutamatergic neurons as responsible but recent data indicate that preBötC frequency can be more dramatically increased via the activation of inhibitory preBötC neurons ([@B10]).

Ectonucleotidases {#S4.SS3}
-----------------

There are seven extracellular ectonucleotidase isoforms in the brain grouped into four families: E-NTPDase-1-3; E-NPP1 and 3; tissue non-specific alkaline phosphatase (TNAP); and ecto-5′-nucleotidase ([@B112]; [@B3]). This diversity, combined with isoform diversity in substrate and end-product preferences and differential distribution in the brain underlies significant clinical potential and ongoing efforts to produce selective ectonucleotidase agonists/antagonists ([@B4]). There is little doubt that ectonucleotidases help determine the balance between ATP and ADO signaling in the preBötC ([@B70]; [@B87]; [@B209]). However, that most ectonucleotidase inhibitors lack specificity and have off-target actions that interfere with respiratory network function means that most evidence is indirect. Evidence that ectonucleotidases affect preBötC network responses to ATP derives primarily from analysis of rhythmically active medullary slices *in vitro* and includes that: (i) hydrolysis-resistant ATP analogs, such as ATPγS ([@B126]) and MRS 2365 ([@B87]) evoke greater frequency responses than ATP; (ii) frequency responses evoked by injection of ATP into the preBötC of rat and especially mouse slices are enhanced by the A1 receptor antagonist, DPCPX ([@B87]; [@B209]); (iii) diffusion of ATP through the preBötC is enhanced in tissue with reduced ectonucleotidase activity ([@B87]); (iv) ATP degradation, measured as the rate of phosphate produced by preBötC tissue punches incubated with ATP, is greatly slowed by the ectonucleotidase inhibitor POM1 ([@B87]); (v) ATP applied to the saline solution bathing rhythmically active slices has very poor access into the tissue; i.e., for an ATP sensor placed just above the slice surface to record the same ATP signal as when the same sensor is placed just 200 μm below the slice surface in the preBötC, the concentration of ATP in the bath must be raised 100-fold, suggesting limited diffusion but more likely significant ATP degradation ([@B70]).

Indirect evidence that differential ectonucleotidase expression is an important factor in shaping network response dynamics to ATP comes from comparing the responses evoked by injecting ATP into the preBötC of slices from rats and mice and correlating these data with real-time PCR data quantifying the relative expression patterns of ectonucleotidase transcripts in the preBötC of the two species. When applied to the preBötC of Wistar or Sprague-Dawley rats, a brief injection of ATP (10 s) evokes a two- to four-fold increase in frequency that peaks in the first 20--30 s and then falls, typically below baseline between 30 and 60 s postinjection before returning to baseline. In mice, however, the same ATP injection either has no effect or a much smaller effect on frequency ([Figure 3A](#F3){ref-type="fig"}) ([@B209]). Importantly, the response of the mouse preBötC to ATP is the same as the rat if A1 ADO receptors are first blocked ([Figure 3C](#F3){ref-type="fig"}). Rat and mouse responses to the selective P2Y~1~ receptor agonist MRS 2365 are also very similar ([Figure 3B](#F3){ref-type="fig"}). Thus, both networks share a common P2 receptor-mediated excitation ([@B209]). In mouse, however, it appears that ATP is degraded so quickly to ADO that the ATP excitation and ADO inhibition almost cancel each other out. That the complement of ectonucleotidases might be a factor in this differential ATP sensitivity is supported by the real-time PCR analysis of mRNA extracted from preBötC. The protein encoded by the dominant ectonucleotidase transcript in mice, TNAP (tissue non-specific alkaline phosphatase), which comprises 80% of total ectonucleotidase mRNA, converts ATPe directly to ADOe. In rats, however, the dominant isoform is ENTPDase 2 (its transcript comprises 55% of total ectonucleotidase mRNA, which has a much higher affinity for ATP than ADP so will preferentially produce ADP, an agonist at excitatory P2Y~1~ receptors ([Figure 3D](#F3){ref-type="fig"}). What remains is to determine protein expression (rather than mRNA) and enzyme activities in these different species as well as between different brain regions. The development of inhibitors that are selective for the different ectonucleotidase isoforms that are also devoid of off-target actions will open the door to answering key questions about the significance and therapeutic potential of manipulating ectonucleotidase activities.

![Differential balance between the actions of ATP and ADO in rhythmically-active preBötC-containing slices from neonatal rat and mouse. Integrated XII nerve recordings (∫XII) from rhythmic slices of rat and mice showing baseline inspiratory-related rhythm *in vitro* and responses to local injection of ATP **(A)** or the P2Y~1~ receptor agonist, MRS-2365, into the preBötC **(B)**. **(C)** Response of a mouse slice to ATP under control conditions and after preBötC injection of the A1 receptor antagonist DPCPX. **(D)** Real-time PCR analysis showing the percentage contribution of each ectonucleotidase isoform to the total ectonucleotidase mRNA extracted from mouse and rat preBötC punches. Error bars indicate SEM. ^∗^Significant difference between the compared columns. Reproduced with permission from [@B209].](fncel-13-00365-g003){#F3}

Adenosine and Adenosine (P1) Receptors {#S4.SS4}
--------------------------------------

ADO actions are mediated via four subtypes of G-protein coupled, P1 receptors. These are the A1 and A2A high-affinity subtypes and the A2B, and A3 low-affinity subtypes ([@B169]; [@B31]). While dogma holds that A1 and A3 receptors act through Gi/Go to inhibit, while A2A and A2B receptors act through Gs to stimulate, the classical adenylate cyclase -- cAMP -- protein kinase A signaling pathway ([@B64]; [@B184]), in the brain cAMP does not appear to be the main transducing system operated by A1 or A2A receptors ([@B40]). P1 receptors may also signal through phospholipase C, Ca^2+^ and mitogen-activated protein kinases (MAPKs) ([@B190]; [@B118]; [@B119]; [@B1]; [@B64]; [@B168]; [@B187]). A2A receptors in the striatum can also couple to G~*olf*~ rather than Gs ([@B109]). All receptor subtypes are present in the CNS, but the high-affinity A1 and A2A subtypes are functionally the most important ([@B64]; [@B184]).

Measurements of ADOe concentrations made using multiple methods, all with limitations, underlie estimates of basal ADOe levels between 30 and 250 nM ([@B113]). During hypoxia, local or global ischemia, or traumatic brain injury the concentration of ADOe is estimated to increase up to 100-fold into the μM range (3--30 μM) ([@B55]; [@B148]; [@B197]). When considered in relation to the binding affinity of the different subtypes for ADO (calculated from *in vitro* binding studies; 3--30 nM for A1, 1--20 nM for A2A, 5 ± 20 μM for A2B and \> 1 μM for A3 ([@B62]), ADOe concentration data suggest that basal levels of ADOe are sufficient to tonically activate A1 and A2A receptors. However, basal ADOe transmission appears to primarily to involve A1 receptors ([@B122]). Lower affinity A2B and A3 receptors may be activated during hypoxia/ischemia/brain injury when ADOe concentrations increase pathologically ([@B113]; [@B148]).

### A1 Receptors {#S4.SS4.SSS1}

A1 receptors are distributed throughout the body with the highest levels of expression in the brain, especially the cortex, hippocampus, cerebellum and dorsal horn of the spinal cord ([@B128]; [@B51]; [@B63]; [@B197]), A1 receptor expression is also high in brainstem regions essential for respiratory control ([@B157]). As reviewed by [@B72], neuronal A1 receptors are located pre-, post- and extrasynaptically. A1 receptors are highly expressed in presynaptic terminals, especially at excitatory synapses (glutamatergic, cholinergic, serotonergic) ([@B72]; [@B184]), where their activation generally inhibits neurotransmitter release ([@B204]; [@B201]; [@B72]), reducing evoked PSPs and the frequency of mEPSPs. The main mechanisms underlying this inhibition include inhibition of voltage-gated Ca^2+^ channels and reduced sensitivity of the vesicular release apparatus to Ca^2+^ ([@B173]; [@B163]; [@B167]; [@B5]). Postsynaptic A1 receptors are primarily located in the postsynaptic density ([@B156]) and their activation reduces the responses of hippocampal neurons to excitatory inputs via the inhibition of N-type Ca^2+^ channels, and NMDA receptor-mediated (but not AMPA receptor-mediated) synaptic inputs ([@B45]).

At the level of the brainstem respiratory network, particularly the preBötC, A1 receptor actions appear dominant ([@B67]). A1 receptor antagonists increase basal frequency *in vitro* and *in vivo* and block the inhibitory actions of ADO on respiratory rhythm ([@B92]; [@B166]; [@B99]; [@B106], [@B103]; [@B196]; [@B87]; [@B209]). In contrast, A2A and A2B receptor agonists have no effect on basal activity of rhythmic medullary slice ([@B135]) or brainstem spinal cord preparations from mice ([@B26]), nor on the ADO-mediated inhibition of mouse slices ([@B135]). As is well-documented in hippocampus and striatum, A1 receptor activation appears to modulate respiratory neuron and network excitability via pre- and postsynaptic mechanisms, but effects differ between subtypes of respiratory neuron, species and with development. Presynaptic A1 receptor-mediated inhibition of synaptic transmission has only been directly shown with mini PSC analysis in phrenic motoneurons in neonatal rats ([@B52]). However, presynaptic A1 receptor mediated inhibition of inspiratory, excitatory and inhibitory inputs to rat XII motoneurons *in vitro* ([@B13]), mouse inspiratory neurons *in vitro* ([@B85]; [@B84]; [@B135]) and cat stage 2 expiratory neurons *in vivo* ([@B166]) is inferred from A1 agonist-mediated reductions in respiratory (excitatory and inhibitory), evoked or spontaneous synaptic inputs ([@B26]). A1 receptor-mediated presynaptic inhibition may also be input- or neuron-specific because the inspiratory synaptic inputs to some inspiratory neurons in the brainstem spinal cord preparation are not unaffected by ADO while excitatory PSPs arriving during expiration are inhibited ([@B26]). Detailed analysis of the effects of ADO and A1 receptor agonists on the frequency and amplitude of miniPSCs in the different subtypes of respiratory neurons is essential to establish which synapses are under presynaptic A1 receptor control.

Postsynaptically, A1 receptor activation hyperpolarizes stage 2 expiratory neurons in adult cat *in vivo* via activation of postsynaptic conductance (likely a K^+^ conductance) that decreases input resistance ([@B166]). Similarly, in the brainstem spinal cord preparation A1 receptor activation hyperpolarizes expiratory neurons and reduces input resistance (effects that persist in TTX), suggesting activation of a postsynaptic K^+^ conductance ([@B84]). The membrane potential and input resistance of biphasic expiratory ([@B84]) and inspiratory neurons are unaffected by ADO in the absence ([@B26]) (or presence) of TTX ([@B84]). In inspiratory preBötC neurons of rhythmic mouse slices, A1 receptors inhibit intracellular cAMP production, which results in K~*ATP*~ activation and membrane hyperpolarization ([@B135]). Similarly, A1 receptor-mediated hyperpolarization of inspiratory neurons in preBötC island preparations from mice is associated with significant reductions in neuronal input resistance ([@B191]). Developmental and species differences must also be taken into account. For example, the A1 receptor-mediated inhibition of inspiratory rhythm in the rhythmic slice or brainstem spinal-cord preparation of rat is gone by postnatal day 2--3 ([@B85], [@B83]; [@B87]), while in mouse it persists until at least 2 weeks of age (Funk and Reklow, unpublished observations).

Postsynaptic A1 receptors are also located at extrasynaptic sites ([@B183]). Their activation in hippocampal neurons enhances background K^+^ currents and causes neuronal hyperpolarization ([@B76]). Basal ADOe tone in the CSF should be sufficient to activate these extrasynaptic receptors and contribute to a tonic, ADO-mediated inhibitory drive. The observation that global inhibition of ADO or A1Rs enhances respiratory rhythm in anesthetized adult cats ([@B166]), unanesthetized fetal sheep ([@B106]), lambs ([@B103]), rats *in vivo*, neonatal rats *in vitro* ([@B92]; [@B196]), as well as fetal breathing movements in embryonic rats *in vivo* ([@B99]) and fictive breathing *in vitro* ([@B87]), suggests that the respiratory network is also under tonic A1 receptor inhibitory control. However, whether this tone reflects activation of synaptic or extrasynaptic receptors is not known. Whether A1 receptors on astrocytes and microglia ([@B189]; [@B79]) influence respiratory network function also remains to be determined.

### A2A Receptors {#S4.SS4.SSS2}

A2A receptors are expressed widely throughout the CNS, but more variably compared to A1 receptors. Expression levels are greatest in the olfactory tubercle and on medium spiny neurons of the striatum ([@B177], [@B178]; [@B160]). The majority of A2A receptors are located in synapses. In the striatum this includes significant pre-synaptic A2A receptor expression, but the majority of A2A receptors are postsynaptic ([@B154]). While A2A expression levels in most other brain regions \[including the cortex and hippocampus that show the highest levels of A1R expression ([@B51]; [@B177])\] are substantially lower than in the striatum, levels are still sufficient to modulate neuronal excitability. For example, activation of presynaptic A2A receptors facilitates glutamatergic transmission in hippocampal CA1 neurons by blocking the inhibitory actions of presynaptic A1 receptors on glutamate release ([@B124], [@B123]). Postsynaptic A2A receptor mechanisms include potentiation of synaptic, but not extrasynaptic, NMDA receptor responses in hippocampal CA1 neurons ([@B140]) and inhibition of the slow afterhyperpolarization in pyramidal neurons of the basolateral amygdala ([@B153]). As reviewed by [@B197] and [@B40], the blockade of A2A receptor-mediated effects appears to have little impact on synaptic transmission under baseline conditions but pharmacological or genetic block of A2A signaling attenuates synaptic plasticity/LTP at specific excitatory synapses. Neuronal and glial expression of A2A receptors can also change dramatically in response to specific conditions/stimuli such as epilepsy, further suggesting an important role in brain plasticity ([@B39]).

Within the brainstem and preBötC, A1 receptor mechanisms appear to dominate but at higher levels of the CNS, possibly at the thalamus ([@B101], [@B102]), A2A receptors also modulate breathing and contribute to the hypoxic respiratory depression. Injection of A2A receptor antagonists into the cisterna magna of sheep, pigs and rats reduces the hypoxic respiratory depression ([@B200]; [@B103]; [@B132]). Importantly, in pigs and rats the actions of the A2A antagonist on the hypoxic respiratory depression are reversed by the GABA receptor antagonist, bicuculline ([@B200]; [@B132]), suggesting that the A2A receptor-mediated inhibition is indirect via excitation of GABAergic neurons. The location of GABAergic neurons that receive the A2A receptor-mediated excitation is not known but it is likely rostral to the medulla and pons since A2 receptor antagonists have no effect on the actions of ADO in the rhythmic medullary slice ([@B135]) or brainstem spinal cord preparation ([@B26]). Lack of an A2A receptor effect under these conditions does not mean A2A receptors have no role in modulation of respiratory networks. Just as A2A receptors appear important in plasticity in cortical circuits ([@B72]; [@B40]), activation of A2A receptors on phrenic motoneurons that drive the main inspiratory pump muscle of mammals can induce phrenic motor facilitation ([@B71]), a form of inducible plasticity in which inspiratory inputs to the phrenic motoneurons are potentiated. The critical role of the brainstem respiratory network in homeostasis has fueled the long-held view of the respiratory network as a hard-wired, immutable structure. This construct is gradually being replaced with the view that plasticity is likely key to the network's ability to adapt throughout life to diverse demands that are constantly changing on multiple time scales (e.g., during development, disease, aging, transitions to altitude, exercise, phonation, speech). A role for A2A receptors in plasticity at the motor output level of this network is clear ([@B71]; [@B90]; [@B65], [@B66]). Exploration of mechanisms that might underlie frequency plasticity within respiratory rhythm generating networks is in its infancy ([@B91]).

The actions of low-affinity A2B and A3 receptors on respiratory networks are not known, but both have been implicated in modulating synaptic plasticity through actions on A1 receptor signaling. A2B receptors are located at glutamatergic terminals of the Schaffer collateral-CA1 pyramidal neuron synapse where they counteract the predominant A1 receptor-mediated inhibition of synaptic transmission ([@B73]). Similarly, an A3 receptor antagonist was reported to reduce the A1 receptor-mediated inhibition of excitatory inputs at these same synapses ([@B53]; [@B125]).

In summary, multiple lines of evidence indicate that ADOe plays an important role in modulating respiratory network activity and in shaping the hypoxic ventilatory response \[see [@B11] for review of other modulators that may contribute\]. ADOe, whether applied exogenously or derived from the hydrolysis of extracellular ATP or from accumulated intracellular ADO that is transported to the extracellular compartment via equilibrative nucleoside transporters, depresses ventilation in virtually all mammals tested, at fetal ([@B17], [@B16]; [@B107]), newborn ([@B81], [@B80]; [@B110]; [@B161], [@B162]; [@B85]), and adult stages ([@B58]; [@B198]; [@B202]). In addition, despite significant species differences in the sensitivity of the secondary hypoxic respiratory depression to ADO antagonists (reviewed in [@B11]), ADO receptor antagonists consistently attenuate the secondary hypoxic respiratory depression ([@B162]; [@B17], [@B16]; [@B107]; [@B203]; [@B105]; [@B103]) and counteract respiratory depression in apnea of prematurity ([@B14]). Despite this abundance of data ([@B106], [@B103]; [@B200]; [@B131]; [@B67]; [@B30]), the relative contribution of ADOe and the four subtypes of ADO (P1) receptor to the respiratory depression and their site(s) of action are not clear. Variations in protocol, drugs, and developmental stage as well as species differences confound the animal literature ([@B67]; [@B82]). A1 receptor signaling appears to dominate in the preBötC ([@B126], [@B127]; [@B87]; [@B209]; [@B6]), where it may be the only P1 receptor mechanism operating, at least in newborn rodents (rats and mice) ([@B135]; [@B26]). Even within the confines of the preBötC, the action of A1 receptor activation varies developmentally and between species ([@B85], [@B83]; [@B84]; [@B87]; [@B209]). There is significant need to understand in many species, throughout development, how the effects of ADO on preBötC activity change, as well as the magnitude of the increase in ventilation that can be achieved by inhibiting ADO receptors within the preBötC. Outside the preBötC, the neuroglial substrate responsible for the A2A receptor-mediated component of the hypoxic respiratory depression has yet to be defined and nothing is known in respiratory networks of the potential actions of A2B and A3 receptors.

Despite the efficacy of ADO receptor antagonists, especially caffeine, as respiratory stimulants that are highly effective in apnea of prematurity, ADO receptors may not be the best target for long-term manipulation of the balance between ATP and ADO signaling. First, as mentioned above, the observation that not all apnea of prematurity patients respond to ADO receptor antagonists highlights the need for alternate, non-ADO receptor focused methods of manipulating this balance. Second, P1 receptors are expressed throughout the body and brain, and potential for cardiovascular side-effects is high ([@B176]). Thus, even if more selective, higher affinity A1 receptor antagonists/agonists become available, it is unlikely that their oral or intravenous delivery would alter breathing without significant side-effects. A2A receptors are less widely expressed than A1 receptors but manipulation of their activity as a means to counteract hypoxic respiratory depression is not known. Blockade of presynaptic A2A receptor actions (which will inhibit glutamatergic transmission) is generally considered as neuroprotective but activation, rather than inhibition of post- and extrasynaptic A2A receptors may be beneficial ([@B72]). In the context of Huntington's Disease, it remains unclear whether A2A agonism or antagonism is clinically favorable. In contrast, A2A receptor antagonists improve motor performance in animal models of Parkinson's Disease ([@B72]), and are under examination for their potential clinical utility as a therapeutic strategy for Parkinson's Disease ([@B179]). In the context of SUDEP, caffeine increases survival time in animal models, hypothetically by reducing the inhibitory actions of ADOe on breathing ([@B171]). However, caffeine ([@B33]), or treatments that reduce ADOe, promote seizure ([@B59]).

### Sources of Extracellular Adenosine {#S4.SS4.SSS3}

A key piece of information lacking for the preBötC (and all parts of the respiratory network) that is critical for the rational development of alternate approaches to manipulate the purinome to enhance P2 and inhibit P1 signaling is the source, or sources, of ADOe. The source of endogenous ADOe during normal synaptic activity, during hypoxia or during any physiological/pathophysiological process is not known. Clearly the source of elevated endogenous ADOe (e.g., via export of ADOi or degradation of ATPe) will dictate the strategies that can be used to modify ADOe. ADOe can derive from multiple sources and release mechanisms that may differ depending on the nature and severity/duration of the stimulus (synaptic activity, hypoxia/ischemia, inflammation, excitotoxicity/traumatic brain injury), brain region and even cell type ([@B113]). That the cellular source of ADOe can vary with stimulus was elegantly demonstrated when cultured neurons, astrocytes, and microglia (from rat) were deprived of oxygen-glucose (OGD, to model energy failure), exposed to H~2~O~2~ (to simulate oxidative stress), or given glutamate (to induce excitotoxicity) ([@B88]). Cultured neurons were the primarily source of ADOe during OGD or glutamate exposure while microglia were the main source during oxidative stress. As reviewed by [@B113] and in agreement with early studies in culture and using hippocampal slices ([@B134]; [@B121]; [@B27]), a majority of studies indicate that during ischemic or hypoxic conditions the main source of ADOe is formed intracellularly and exported. Importantly, while glia may be a dominant source of ADOe during hypoxia, elevated ADOe during hypoxia could come from endothelial cells, glial cells, and also neurons from anywhere along their cell membrane; i.e., not limited to synapses ([@B113]). ADO release during hypoxia is only partially sensitive to TTX and Ca^2+^-independent. This pattern of release differs markedly from normoxic conditions when depolarizing stimuli evoke an ADOe increase that is completely blocked by TTX, Ca^2+^-sensitive and derived from presynaptic neuronal release of ATP that is subsequently degraded (i.e., ADOe production is sensitive to ecto-5-nucleotidase inhibitors) ([@B134]; [@B121]; [@B27]; [@B113]; [@B145]; [@B194]; [@B208]; [@B117]). The proposal that ADO can be released via exocytosis from synaptic vesicles ([@B195], [@B194]; [@B98], [@B97]; [@B37]) remains controversial, reflecting in part the speed with which ATP can be converted into ADOe and therefore the difficulty of excluding ATP as a source of ADOe ([@B40]). It was shown early on that the actions of ATP at P2 receptors in different brain regions are followed by inhibitory actions that are caused by the rapid degradation of ATP via ectonucleotidases into ADO and activation of P1 receptors ([@B54]; [@B41]). The kinetics of this biphasic ATP-ADOe signaling action appear strongly influenced by the properties of ecto-5′-nucleotidase, the main extracellular enzyme that converts AMP into ADO. During periods of intense presynaptic activity and high ATP/ADP levels, it was proposed that ADO production from AMP is delayed until activity ceases and ATP/ADP levels decline, which removes the ATP/ADP inhibition of ecto-5′-nucleotidase ([@B54]; [@B113]). Such a biphasic response is clearly seen when ATP is applied exogenously into the preBötC of neonatal rats, but not in Swiss CD mice where the excitatory actions of ATP and inhibitory actions of ADOe more or less cancel each other out ([@B209]). This difference may reflect differential expression of ectoATPases in the two species. As mentioned above, the dominant ectonucleotidase transcript in mice is TNAP, which converts ATPe directly to ADOe. The dominant isoform in rat is ENTPDase 2, which preferentially produces ADP from ATP ([@B209]). The kinetics of the ATP/ADO interaction that evolves in the preBötC in response to endogenously released ATP, and the involvement of specific ectoATPases in this relationship is not known. However, there is evidence that enzyme activity may be distributed to achieve spatially specific adenosine receptor activation. In hippocampus, production of ADOe by ecto-5′-nucleotidase has presynaptic inhibitory actions but also contributes to A2A receptor-mediated long-term potentiation of NMDA EPSCs ([@B155]). In the striatum, ecto-5′-nucleotidase is localized to astrocytes but also prominently localized to A2A receptor-containing postsynaptic terminals where it mediates hypolocomotion and modulates working memory ([@B9]).

Although the majority of studies (primarily in hippocampus) indicate that the main source of ADOe during ischemic or hypoxic conditions is formed intracellularly ([@B134]; [@B121]; [@B27]), this may not be case for regions involved in respiratory control. During hypoxia in fetal sheep, an important source of ADOe in the thalamic parafascicular locus, where A2A receptors contribute to the secondary hypoxic respiratory depression ([@B101]), appears to be extracellular; i.e., the hypoxia-induced increase in ADOe is unaffected by ENT inhibitors but reduced by inhibitors of ecto-5′- nucleotidase ([@B104]). Within the preBötC we also propose an extracellular source of ADOe during hypoxia; i.e., that hypoxia evokes ATP release from astrocytes via exocytosis, which is then degraded to ADOe. Whether ATPe released via exocytosis, and the subsequently produced ADOe, will diffuse to extrasynaptic receptors and have broad, generalized effects over the entire network, or have localized actions on specific preBötC neurons/synapses is not known. However, within the framework of the localized, bidirectional communication that is proposed to occur between pre- and postsynaptic terminals and astrocytes in the tripartite synapse ([@B8]; [@B38]), and the observation that preBötC respiratory neurons differ markedly in their sensitivity to ATP/P2Y~1~ and ADO receptor activation ([@B84]; [@B135]; [@B186]; [@B126], [@B127]), neuroglial interactions in the preBötC are likely to be highly specialized, regionally and functionally; i.e., the effects of ATP/ADP/ADO released from astrocytes during hypoxia are likely to reflect activation of specific synapses and neurons.

Equilibrative Nucleoside Transporters {#S4.SS5}
-------------------------------------

There are four ENT isoforms that move ADO passively, and bidirectionally across cell membranes. The direction of ADO transport is determined by the ADO concentration gradient. ENT1 and 2 carry out the majority of ADO transport across the outer cell membrane ([@B144]). ENT3 is intracellular and irrelevant in determining ADOe while ENT4 appears to function primarily in monoamine transport. Three isoforms of concentrative nucleoside transporters (CNTs) in the CNS are Na^+^-coupled and indirectly consume ATP to move ADO against its concentration gradient, but there is no evidence that CNTs regulate ADOe under normal physiological conditions ([@B144]; [@B34]). Thus, our focus is on ENTs. They play a key role in maintaining ADOe under baseline conditions, as demonstrated by \> 4-fold increases in ADOe in the striatum of freely behaving rats following transporter inhibition ([@B12]). Thus, they are increasingly recognized as potential targets in drug discovery, in part because ADOe is implicated in a range of significant health issues, including cardiovascular disease and sleep disorders ([@B94]).

Manipulation of ENTs to control ADOe requires that the source of the increased ADOe during hypoxia is known ([@B147]; [@B146]; [@B130]; [@B67]). As discussed above (*Sources of extracellular ADO*), if the main source of ADOe is from the ENT-mediated export of ADOi that accumulates during hypoxia, then ENT inhibition would be required to reduce ADOe in the preBötC. If, however, the main source of ADOe is from degradation of ATPe, then the objective would be to potentiate inward ENT-mediated transport and facilitate the clearance of ADOe. Multiple sources and mechanisms can contribute to an hypoxia-induced increase in ADOe. While ENT-mediated export may be a dominant source of ADOe during hypoxia/ischemia in some parts of the brain ([@B134]; [@B121]; [@B27]; [@B113]), this may not be the case in the respiratory network. The role of ENTs in regulating ADOe during hypoxia has not been examined specifically in the preBötC. Under baseline conditions in the brainstem spinal cord of neonatal rats, the ENT inhibitor, dipyridamole, decreases inspiratory-related burst frequency, indicating that at least under these conditions ENT activity is important for clearing ADOe ([@B85]). In fetal sheep during hypoxia, however, a major source of ADOe implicated in the hypoxic respiratory depression ([@B101]) is from degradation of extracellular adenine nucleotides ([@B104]).

To gain insight into the potential source of ADOe during hypoxia in rodents, we have recently used whole-body plethysmography ([@B210]; [@B6]) to compare the hypoxic ventilatory responses of adult, wild-type and three strains of transgenic mice from which ENT1, ENT2 or ENT1 and 2 were both knocked out from birth. All experiments were carried out in accordance with the guidelines of the Canadian Council on Animal Care and were approved by the University of Alberta Animal Ethics Committee (Protocols AUP256). Animals were placed in a whole-body, plexiglass plethysmograph that had inflow and outflow ports for continuous delivery of a steady flow of air (21% O~2~, balance N~2~ or 10% O~2~/balance N~2~). Pressure changes in the chamber were recorded with a pressure transducer (DP 103; Validyne, Northridge, CA), signal conditioner (CD-15; Validyne), analog-digital board (Digidata 1322), and Axoscope software (Molecular Devices, Sunnyvale, CA). Animals were allowed 30 min to become accustomed to the chamber. Baseline ventilatory parameters (frequency, relative tidal volume and relative minute ventilation) were then recorded for 10 min and gas composition was changed to 10% O~2~/balance N~2~ for 10 min and then returned to 21% O~2~. Air flow and composition were controlled to produce a rapid transition from 21 to 10% O~2~ (\< 15 s). Note that measurements of frequency are quantitative while changes in tidal volume and minute ventilation (the product of frequency and tidal volume) are semiquantitative (reported relative to baseline). The increase in ventilation from baseline to the peak observed during Phase 1 of the hypoxic ventilatory response was reported as 100%. Ventilation during Phase 2 (average between min 6--10 of hypoxic exposure) was calculated as a percentage of the peak increase recording during Phase 1 ([Figure 4A](#F4){ref-type="fig"}). All strains showed a biphasic ventilatory response to hypoxia but the magnitude of the hypoxic respiratory depression was greatest in the ENT1/2 KO mice \> ENT1 KO \> ENT2 KO ≈ wild type mice ([Figure 4B](#F4){ref-type="fig"}). The size of the blue bar indicates the magnitude of the depression; i.e., ventilation of the WT mice during Phase 2 was ∼70% of the peak seen during Phase 1 (i.e., during the hypoxic respiratory depression, ventilation fell ∼ 30% from the peak). In contrast, ventilation in the ENT1/2 KOs was 0% of peak, indicating that during Phase 2 ventilation fell all the way to baseline levels (100% depression). These data suggest that the main source of ADOe causing the hypoxic depression comes from breakdown of ATPe. If ADOe came via ENT-mediated outward transport of ADOi, one would expect the opposite -- that ADOe would not increase in the ENT KOs and there would be no depression. The main limitation with these data is that ENTs are knocked out globally from birth in these animals, including from the carotid body. Thus, additional work with conditional and/or localized deletion/inhibition of ENT activity will be required to fully evaluate in respiratory networks the source of elevated ADOe during hypoxia, and the role of ENTs in the hypoxic ventilatory response. Such information is required to inform strategies on how to manipulate ENT function to reduce hypoxic respiratory depression.

![Global knock out of ENTs increases the secondary hypoxic respiratory depression. **(A)** Cartoon showing the biphasic hypoxic ventilatory response, which comprises a Phase 1 increase followed by a secondary depression to a lower, steady-state level of ventilation in Phase 2. The Phase 1 increase was reported as 100%. Ventilation during Phase 2 was calculated as a percentage of the peak increase during Phase 1. In this mock example, ventilation during phase 2 was ∼45% of the phase 1 increase; i.e., ventilation fell by ∼55% from the peak during the hypoxic respiratory depression. **(B)** The level of ventilation (measured using whole-body plethysmography) during Phase 2 of the hypoxic ventilatory response is reported relative to the Phase 1 peak increase for unanesthetized wild type (WT), ENT2, ENT1, and ENT1/2 double knockout mice. ^∗^Represents sig. difference from WT, *p* \< 0.05 or ^∗∗^*p* \< 0.01. ANOVA was used in conjunction with Bonferroni *post hoc* multiple comparison test.](fncel-13-00365-g004){#F4}

Adenosine Kinase {#S4.SS6}
----------------

The impact of manipulating ENT activity on ADOe emphasizes the importance of ADOe metabolic clearance mechanisms in regulating ADOe under baseline, hypoxic and pathological conditions. ENT activity, however, is only part of the ADOe clearance equation. The direction of ADO transport by ENTs is determined by the ADO concentration gradient across the cellular membrane; ADOi must be maintained below ADOe for ENTs to effectively remove ADOe. As demonstrated in rat hippocampal slices ([@B120]), ADOi and ADOe are influenced by several intracellular enzymes. These include S-adenosyl homocysteine hydrolase, the low affinity, high capacity metabolic enzyme adenosine deaminase, that converts ADO into inosine, and the high affinity, low capacity enzyme ADK that phosphorylates ADOi to AMPi. Our discussion focuses on ADK because it has a higher affinity for ADO than adenosine deaminase, and in hippocampal and cortical networks it is the most important enzyme affecting intracellular levels of ADO and in controlling neuronal excitability and ADO signaling ([@B143]; [@B23]). It is important to note that in the adult brain ADK is primarily expressed in astrocytes. Therefore ADOe and hence activation of ADO receptors on neurons is under the control of astrocyte-based metabolic clearance of ADOe. Dysregulation of ADK may be causative in some forms of epilepsy. The ADK hypothesis of epilepsy posits that acute insults to the brain lead to an initial and transient downregulation of ADK and an acute elevation of ADOe that is protective in the short term. However, the acute changes trigger maladaptive long term changes of the purinome including downregulation of astrocytic A1 receptors, upregulation of A2A receptors, and astrogliosis in conjunction with chronic overexpression of ADK, reduced ADOe and ultimately spontaneous focal seizure activity in astrogliotic regions ([@B18]). Pharmacological inhibition of ADK ([@B108]), or ADO augmentation therapies developed to inhibit ADK and raise ADOe greatly reduce seizures in animal models of epilepsy ([@B21]), whereas transgenic overexpression of ADK triggers seizures ([@B59]). Whether ADK inhibition increases the risk of respiratory depression, and therefore SUDEP, is not known.

In fact, virtually nothing is known about the impact of ADK on either the baseline control of breathing or the hypoxic ventilatory response. Most exciting in terms of respiratory control is that the ADK system changes dramatically during postnatal development ([@B23]). ADK comes in long nuclear and short cytoplasmic isoforms, ADK-L and ADK-S, respectively. The nuclear isoform ADK-L has an epigenetic role as regulator of DNA methylation, whereas the cytoplasmic form ADK-S is responsible for regulating extracellular levels of adenosine and ADO receptor activation ([@B23]; [@B199]). During fetal and early postnatal brain development there is a shift in the expression from ADK-L to more ADK-S and from neuronal expression toward astrocytic expression, suggesting a functional change from an epigenetic regulator of brain development toward a regulator of extracellular adenosine. Therefore, the major system responsible for clearing ADOe in the hippocampus is immature at birth. If the maturation of ADK follows a similar developmental profile in the brainstem respiratory network, it could contribute to the greater susceptibility of premature animals to hypoxic respiratory depression ([@B138]). Tools developed to study the role of ADK in epilepsy, including transgenic mouse lines ([@B188]; [@B25]; [@B60]) and adenoassociated viral vectors that knockdown ADK specifically in neurons or astrocytes ([@B185]), should be very instructive in advancing our understanding of the role played by ADK in respiratory control and the hypoxic ventilatory response.

In summary, we have reviewed evidence that purinergic signaling within the preBötC network modulates breathing rhythm and shapes the ventilatory response to hypoxia. Purinergic signaling in other brain regions may contribute to this reflex, but our discussion has focused on the preBötC because it is within this region that we have the strongest evidence that P2 and P1 receptor signaling and ectonucleotidase activity shape the hypoxic ventilatory response. Even for these components of the purinome many questions remain. These include: (i) the identity of signaling cascades and ion channels through which the different receptors modulate breathing rhythm; (ii) the significance of ectonucleotidase diversity for respiratory control; and (iii) the source of ADOe during hypoxia -- degradation of ATPe or outward ENT-mediated transport of ADOi. Studies exploring the roles in the hypoxic ventilatory response of ADO transporters (the ENTs), and intracellular enzymes important in controlling ADOi and ADOe clearance (e.g., ADK) are only in their infancy. The developmental dynamics of purinergic signaling in the respiratory network also requires investigation, especially given the potential involvement of the purinome in the greater susceptibility of premature and newborn mammals to hypoxic respiratory depression. Additional key areas of future investigation not discussed above include how the effects of purinergic signaling on cerebral vasculature will affect network excitability, and how the mechanisms and dynamics of purinergic signaling differ between conditions like hypoxia, when ATP is released through physiologically relevant processes, and traumatic injury where ATP is released in high concentration from damaged/ruptured cells including red blood cells? A key translational challenge is to selectively manipulate the balance between ATP/ADO signaling to stimulate ventilation without simultaneously interfering with the beneficial actions of ADOe in other brain regions. To do so will require detailed understanding, not only of the purinome within the preBötC and other respiratory nuclei, but the rest of the brain as well.
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